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and distant metastasis-free rates were 86%, 67%, and 38% at 
1 year and 86%, 38%, and 16% at 3 years, respectively. 
Thirteen patients died; the cause of death was tumor 
progression in 10 patients, infectious pneumonia in two, and 
old age in one. The overall and cause-specific survival rates 
were both 73% at 1 year and 23% and 44% at 3 years, 
respectively. The median survival time was 16 months. 
Although all 17 patients developed grade 1–2 radiation 
dermatitis, there were no therapy-related toxicities of grade 
≥3. 
 
Conclusion: Total scalp irradiation with X-rays and electrons 
is safe and effective for local tumor control of angiosarcoma 
of the scalp, but a prophylactic dose of ≤50 Gy in 
conventional fractions may be insufficient to eradicate 
microscopic disease. For gross tumors, a total dose of 70 Gy, 
and >70 Gy for tumors with deep invasion, is recommended. 
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Purpose or Objective: Uveal melanoma (UM) is a life 
threatening intraocular malignant tumor in adults. Gamma 
Knife Stereotactic Radiosurgery (GKSRS) is a well assessed 
strategy for conservative treatment of UM providing 
satisfactory results in terms of survival, local control and eye 
preservation. Despite severe side effects following GKSRS 
have been reported, literature studies designed to 
investigate dose effect relationship of critical structures are 
rather poor. The aim of this work is to develop predictive 
models for radio induced effects in UM patients (pts) treated 
with GKSRS. 
 
Material and Methods: In our institute 149 pts were treated 
with exclusive GKSRS for UM between 1994 and 2014. 
Prospectively collected clinical data are available. For 
66/149 pts, 3D dosimetry data of involved critical structures 
could be recovered: optic nerve (ON), eyeball and posterior 
part of bulb. For this cohort of pts the median follow up of 
2years (6 months-6 years) is available. Cox’s analyses were 
used to identify selected clinical and dosimetric variables as 
independent risk factor of main side effects: cataract, 
radiation vasculopathy (RV), radiation papillopathy (RP) and 
neovascular glaucoma (NVG), visual acuity (VA) reduction > 
20% of basal value (VA20%) and complete loss of basal VA 
(VA100%). ROC curve analysis allowed predicting cut off value 
of significant variables. 
 
Results: The 2 years incidences from our data were: cataract 
39%, RV 10%, RP 12%, NVG 14%, VA20% 59% and VA100% 27%. 
Age and sex did not result significant. Concerning cataract 
the volume of whole bulb receiving more than 30Gy 
(p=0.0004) and tumor thickness (p=0.002) resulted highly 
predictive; best cut off were respectively 82.2mm3 and 
6.6mm. A clear relationship with maximum dose (Dmax) to 
ON was found for RP (p=0.009 cut off: 14.9Gy) and RV 
(p=0.0009 cut off: 23.8Gy). For RV, also tumor in the anterior 
to equator position was predictive (p=0.008). The volume of 
the posterior bulb receiving more than 20Gy (p=0.0003, cut 
off: 413.7mm3) and tumor thickness (p=0.0009 cut off: 
8.7mm) were predictive for NVG. Multivariate analyses 
resulted in two variables predictive model both for VA20% 
(AUC=0.79) and for VA100% (AUC=0.83), including the tumor 
longest basal diameter and Dmax to the ON. The best cut off 
values for the tumor longest basal diameter were 11.6mm for 
VA20% (p=0.02) and 8.98mm for VA100% (p=0.007); the best 
cut off values for Dmax to the ON were 7.8Gy (p=0.045) for 
VA20% and 13.2Gy (p=0.002) for VA100%. A summary of the 





Conclusion: We found clinical and dosimetric variables to 
clearly predict the risk of the main side effects after GKSRS 
for UM. These results may provide new dose constraints to 
critical structures, that once implemented during treatment 
planning, could reduce radiation toxicities. Further 
investigation to create bulb dose surface maps highlighting 
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Purpose or Objective: Choroidal melanoma is the most 
frequent malignant tumour of the eye. Eye-conserving 
treatment with Ruthenium-106 brachytherapy (RuBT) is a 
standard treatment for patients with small to intermediate 
size melanomas. The present study was done to evaluate 
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efficacy and visual outcomes of a large series of patients with 
choroidal melanoma (CM) treated with RuBT, and compare 
the results to those of the preceding protocol in which RuBT 
was combined with transpupillary thermotherapy (Ru/TTT). 
 
Material and Methods: Outcomes of 449 consecutive CM 
patients with tumour prominence <8 mm and basal diameter 
<16 mm treated with RuBT from 2004 to 2011 were analysed. 
253 (56.3%) were treated according to the current RuBT 
protocol (from 2008 onwards) with 130 Gy specified at the 
tumour apex and minimum and maximum doses to the scleral 
surface of 300 Gy and 1000 Gy, respectively. 196 (43.6%) 
were treated using the preceding Ru/TTT protocol with 
either 400 or 600 Gy to the scleral surface followed by TTT, 
or 600-800 Gy without TTT for peripheral tumour location. 
The brachytherapy dose was standardized to a dose rate of 
100 Gy per 24 h using a correction factor (2-10% dose 
correction). Local failure was defined as residual prominence 
with signs of activity on fluorescence angiography, or 
regrowth after complete remission. 
 
Results: Median follow-up was 40.1 months; 25.9 months for 
RuBT and 67.5 months for Ru/TTT; hence 3-year results were 
analysed. Patients treated with RuBT had smaller and less 
centrally located tumours and better median visual acuity 
(VA). VA deteriorated more rapidly in Ru/TTT patients; at 1 
year the loss of vision relative to the VA before treatment 
was -0.1 for RuBT patients vs -0.25 for Ru/TTT, while at 3 
years the relative VA decline was similar (-0.30 vs. -0.28). 
Local failure was detected within 3 years in 4.3% of RuBT 
patients compared to 11.2% of Ru/TTT patients, for 3-year 
cumulative incidence rates of 6.4% vs 11.2% (p=0.09). 
Treatment for local failure consisted of repeated RuBT; TTT; 
or enucleation. Enucleation was performed in 2.4% of RuBT 
patients vs. 10.2% of Ru/TTT; of these, 1.6% vs 6.1% were 
done for recurrence and 0.8 vs 4.1% for complications. Three-
year cumulative incidence of distant metastases was 4.8% vs 
6.6% for RuBT vs Ru/TTT (p=0.37), and of death 0.5 vs 3.7%. 
In univariate analyses, most important risk factors for local 
recurrence and metastases were tumour prominence, tumour 
diameter and stage, while in multivariate analysis only 
diameter remained significant for local recurrence. In view of 
the short follow-up of RuBT, updated results will be 
presented. 
 
Conclusion: Both protocols for eye-conserving treatment of 
patients with choroidal melanoma provided excellent rates of 
local tumour control and eye preservation, with the RuBT 
protocol confirmed to be best standard of care with 97% eye 
preservation and significantly longer preservation of visual 
acuity. 
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Purpose or Objective: The standard primary treatment for 
soft tissue sarcoma (STS) is radical surgical resection, 
preceded or followed by radiotherapy. The purpose of this 
retrospective study was to assess the efficacy and safety of 
perioperative brachytherapy (BT) plus postoperative external 
beam radiation therapy (EBRT) +/- chemotherapy (CT). 
 
Material and Methods: The primary aim of the study was 
evaluating local control (LC) and overall survival (OS) in a 
large patients population of treated with combined modality 
therapy. Secondary objectives were to identify prognostic 
factors for local recurrence (LR). BT was delivered with 
Pulsed Dose Rate. Total dose was 20 Gy (0.80 Gy/pulse). 
EBRT was delivered with 3D-technique by using multiple 
beams technique. The prescribed dose was 46 Gy 
(2Gy/fraction). Neoadjuvant and adjuvant chemotherapy was 
prescribed to patients with potentially chemo-sensitive 
histological subtypes. Univariate analysis was performed with 
the log-rank test and multivariate analysis with Cox’s 
proportional hazard model.  
 
Results: From 2000 to 2011, 107 patients (median age 54 
years; range 13-85) with high grade primary or recurrent STS 
were treated with surgery, perioperative BT and adjuvant 
EBRT +/- CT. Five year LC and OS were 82.2% and 87.8%, 
respectively. A higher LC was recorded in patients treated for 
primary tumor, lower limbs, and negative margins STS. 
 
Conclusion: The combination of BT and EBRT was able to 
achieve high LC and OS rates. A particular risk factor 
recorded was the disease site. These results warrant further 
prospective studies to define the role of BT boost in adjuvant 
therapy of resected STS.  
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Purpose or Objective: Primary cardiac and great vessel 
sarcomas are a challenging group of cancers with poor 
prognosis. No consensus management guidelines exist and 
definitive treatment favours surgery, reserving adjuvant 
radiotherapy (RT)/chemotherapy (CT) for high-risk patients. 
 
Material and Methods: Retrospective analysis of patients 
identified from a prospectively collected database Sarcoma 
Unit, 2000-2014. 
 
Results: 33 patients(19 males) were identified with either 
primary cardiac(73%) or great vessel sarcomas; median age of 
46.9 (range 13-83). Presenting symptoms included 
dyspnoea(55%), pain(21%), cough/haemoptysis(11%), heart 
failure(24%), emboli(18%) or pulmonary HTN(12%). Diagnosis 
was on biopsy(42%) or following resection(58%). Atrial 
tumours accounted for 58% of cases. Surgery was performed 
in 66%, with R0(12%),R1(24%) ,R2(24%), or unknown (6%) 
margins. High grade tumours were seen in 17(52%) cases. 
Commonest histological subtypes were angiosarcoma (32%), 
and spindle cell (17%). Localised disease was observed in 18 
(55%) cases. Median follow-up was 379 days. 
Group A, Radiotherapy: 15 patients received RT (6 males), 10 
had operable tumours. 8 patients also received CT. Median 
time to first treatment was 57.9 days. Patients received 60 
Gy/30#(n=4), 59.4 Gy/33#(n=3), 58 Gy/30#(n=1), 50.4 
Gy/28#(n=3), 45 Gy/25#(n=1), 35 Gy/15#(n=1), or 20 
Gy/5#(n=1). 85% reported toxicity (oesophagitis, cough or 
fatigue). 8 (53%) patients developed a local recurrence (LR) 
and 13 patients developed metastatic disease (DM). 2 were 
long term survivors. Median time to DM for right sided lesions 
was 116 days, left sided, 1226 days. Overall survival was 2.1 
years (R side) and 3.4 years (L side). Median OS was 803 days.  
Goup B, Chemotherapy: 13 patients received CT(10 males), 7 
had operable tumours. Median time to first treatment was 44 
days. Regimens were mainly alkylating/anthracycline/taxane 
based. 3 patients stopped early (toxicity). 10 patients had 
LR(77%) and 10 patients developed DM. 2 were long term 
survivors. Median OS was 296 days. 
Group C, Surgery: 
